bullish
Classys (214150 KS): Beautiful Journey Continues; Record High Revenue and Operating Profit in 1Q24
287 Views09 May 2024 15:35
SUMMARY
- Classys (214150 KS) started 2024 on a strong note with highest ever quarterly revenue and operating profit in 1Q24. Faster-than-expected consumables orders from overseas markets drove the overall performance.
- The proportion of consumable sales rose to 53% (1Q23: 48% and 4Q23: 43%), increasing by 42% and 32% QoQ. Increasing contribution from high-margin consumables sales improved the profitability substantially.
- Favorable industry tailwind, global expansion, and new launches remain main growth drivers. Classys still expects 2024 revenue of KRW225B, up 25% YoY. In April, Classys obtained FDA approval for Volnewmer.
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Discussions
(Paid Plans Only)
Rising
Tina Banerjee
Global Healthcare Analyst
Price Chart(Sign Up to Access)
- ABL Bio Capital Raise of 140 Billion Won03 Jul 2024
- Arb Spread Has Opened Today in Classys & Ilooda Merger Swap: Checking Trade Feasibility27 Jun 2024
- Merger Between Classys and Ilooda Likely to Reduce Local Competition26 Jun 2024
- Classys: One of Korea's Top Beauty Medical Device Makers + Higher Shares Cancellation and Dividends08 Mar 2024
- Classys (214150 KS): 2023 Sales Beat Guidance to Reach Record High; Stellar Performance to Continue01 Mar 2024
- Classys (214150 KS): Record High Quarterly Performance in Q3; 2024 to Continue to Be Radiant26 Nov 2023
x